Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -120% Improvement Relative Risk c19hcq.org Barrat-Due et al. NCT04321616 HCQ RCT LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Double-blind RCT 93 patients in Norway Higher mortality with HCQ (not stat. sig., p=0.35) Barrat-Due et al., Annals of Internal Medicine, doi:10.7326/M21-0653 Favors HCQ Favors control
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19
Barrat-Due et al., Annals of Internal Medicine, doi:10.7326/M21-0653, NCT04321616 (history)
Barrat-Due et al., Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19, Annals of Internal Medicine, doi:10.7326/M21-0653, NCT04321616
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT in Norway with 52 HCQ and 42 remdesivir patients, showing no significant differences with treatment. Add-on trial to WHO Solidarity. NCT04321616 (history).
risk of death, 120.0% higher, RR 2.20, p = 0.35, treatment 4 of 45 (8.9%), control 2 of 48 (4.2%), adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Barrat-Due et al., 13 Jul 2021, Double Blind Randomized Controlled Trial, Norway, peer-reviewed, 41 authors, average treatment delay 8.0 days, trial NCT04321616 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: ORIGINAL RESEARCH Annals of Internal Medicine Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 A Randomized Trial Andreas Barratt-Due, PhD; Inge Christoffer Olsen, PhD; Katerina Nezvalova-Henriksen, PhD; Trine Kåsine, MD; Fridtjof Lund-Johansen, PhD; Hedda Hoel, PhD; Aleksander Rygh Holten, PhD; Anders Tveita, PhD; Alexander Mathiessen, PhD; Mette Haugli, MD; Ragnhild Eiken, MD; Anders Benjamin Kildal, PhD; Åse Berg, PhD; Asgeir Johannessen, PhD; Lars Heggelund, PhD; Tuva Børresdatter Dahl, PhD; Karoline Hansen Skåra, MSc; Pawel Mielnik, MD; Lan Ai Kieu Le, MD; Lars Thoresen, MD; Gernot Ernst, MD; Dag Arne Lihaug Hoff, PhD; Hilde Skudal, MD; Bård Reiakvam Kittang, PhD; Roy Bjørkholt Olsen, PhD; Birgitte Tholin, MD; Carl Magnus Ystrøm, MD; Nina Vibeche Skei, MD; Trung Tran, PhD; Susanne Dudman, PhD; Jan Terje Andersen, PhD; Raisa Hannula, MD; Olav Dalgard, PhD; Ane-Kristine Finbråten, PhD; Kristian Tonby, PhD; Bjorn Blomberg, PhD; Saad Aballi, MD; Cathrine Fladeby, PhD; Anne Steffensen, MSc; Fredrik Müller, PhD; Anne Ma Dyrhol-Riise, PhD; Marius Trøseid, PhD; and Pål Aukrust, PhD; for the NOR-Solidarity trial* Background: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drugs are not known. Objective: To evaluate the effects of remdesivir and HCQ on all-cause, in-hospital mortality; the degree of respiratory failure and inflammation; and viral clearance in the oropharynx. Design: NOR-Solidarity is an independent, add-on, randomized controlled trial to the WHO Solidarity trial that included biobanking and 3 months of clinical follow-up (ClinicalTrials. gov: NCT04321616) Setting: 23 hospitals in Norway. Patients: Eligible patients were adults hospitalized with confirmed SARS-CoV-2 infection. Intervention: Between 28 March and 4 October 2020, a total of 185 patients were randomly assigned and 181 were included in the full analysis set. Patients received remdesivir (n = 42), HCQ (n = 52), or standard of care (SoC) (n = 87). Measurements: In addition to the primary end point of WHO Solidarity, study-specific outcomes were viral clearance I n February 2020, a World Health Organization (WHO) expert group recommended that 4 drugs approved for other indications—hydroxychloroquine (HCQ), remdesivir, ritonavir-boosted lopinavir, and interferon-b 1a—should be evaluated in an international, adaptive, open-label, randomized clinical trial and compared with standard of care (SoC) in the treatment of hospitalized patients with SARS-CoV-2 infection. This initiative resulted in initiation of the WHO Solidarity trial (1). The HCQ and lopinavir groups of this trial were subsequently stopped because of reported lack of effect based on emerging external evidence from the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial, as well as internal evidence from interim analyses (2). In October 2020, the WHO Solidarity trial consortium published interim results, reporting that all of the repurposed drugs evaluated showed little or no effect on inhospital mortality and did not reduce the need for mechanical in oropharyngeal specimens, the degree of respiratory failure, and inflammatory variables. Results: No significant differences were seen between treatment groups in mortality during hospitalization. There was a..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit